Novartis AG (NVS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novartis AG has reported a robust start to 2024 with double-digit sales growth and a significant expansion of core margins in the first quarter, prompting an upward revision of their full-year guidance. The company’s net sales rose by 11%, with core operating income increasing by 22%, fueled by strong sales momentum across key growth brands. Despite a 24% decrease in free cash flow due to timing of payments and a prior-year one-time item, Novartis is experiencing broad-based performance improvements and pipeline advancements.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.